KRAS Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a full length recombinant KRAS.
- CITATIONS: 1
|Application ||WB, IF, E|
|Calculated MW||21656 Da|
|Other Names||GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally processed, KRAS, KRAS2, RASK2|
|Target/Specificity||KRAS (AAH13572, 1 a.a. ~ 188 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||KRAS Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Provided below are standard protocols that you may find useful for product applications.
This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.
1.Evidence for aldosterone-dependent growth of renal cell carcinoma.King S, Bray S, Galbraith S, Christie L, Fleming SInt J Exp Pathol. 2014 May 7. doi: 10.1111/iep.12074.2.KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio FInt J Cancer. 2013 Feb 12. doi: 10.1002/ijc.28106.3.Analysis of k-ras nuclear expression in fibroblasts and mesangial cells.Fuentes-Calvo I, Blazquez-Medela AM, Santos E, Lopez-Novoa JM, Martinez-Salgado C.PLoS One. 2010 Jan 14;5(1):e8703.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.